generics," that have chosen to remove the name from the label. otherwise, they are, our interest. the broader interest that we have is in encouraging real competition, which means multiple manufacturers creating many different versions of epinephrine auto injectors, including true generics, generics approved under the fda. theou would argue competition is not as good or not the same thing? simply atre looking the numbers of manufacturers in the area, there are two manufacturers currently making forephrine auto injectors prescription in the u.s.. there is a third product that is approved that was voluntarily withdrawn last fall because of manufacturing issues. they addressed those issues, if they did, they would be able to come back on the market. >> you expect them to? >> we are offering any

assistance we can for them to do that. my next question, a more difficult question. im not suggesting any governmental problem. murraya book by charles a little while ago. he talked about the moral decline of america. a lot of that moral decline, he focused on the underclass. somethinge is not many people in my age group had when we were growing up, he focused a little bit on the upper class. things that he focused on, which i think, collectively is not a huge amount of money, maybe it had a penny to each prescription drug you have, but i think it is bad for the fabric of society. i realize it is legal and i am not just targeting you because it is common across the board. it came up earlier that you are

making whatever, $90 million, $20 million a year. that is a half cent off of every prescription you guys make. the point marie made was that made was it -- murray that chief executive got along making a lot less, and they make a lot less insightful companies around the globe. the point he made was that this greed, and while it amountrelatively small for every person in the country, it probably tears a little bit the moral fabric as people who work for companies and make relatively small amounts of money look at the chief thantive making more money anybody could possibly imagine. do you ever feel guilty or have feelings of guilt making such a large sum of money?

who founded the company, but as an employee that does not have a lot of risk yourself? am blessed look, i and fortunate. i have been working of his company for 25 years representing 40,000 employees. mylan has continued to provide access to multiple medications here in the u.s., over 600 products. mr. grothman: i'm sure there are many employees that do wonderful things, valuable scientists saving people's lives. i am saying, as he walked around the cubicles and the all you $40,000 year, $50,000 a year, do you feel guilty that you and the board of directors have arranged to make you make millions of dollars a year? ms. bresch: i love that mylan is trying to make a difference and howy in what we do much product and access we are bringing and the savings to this

company alone -- this country alone, $180 billion. mr. grothman: do you understand what i'm saying? understand.n't maybe you are very good and maybe you are worth it. one of the things that frustrates a lot of americans is that there are a lot of people who run their company into the ground and make tens of millions of dollars, but i'm going to ask you to comment again. you think it is good for the moral fabric of society and the idea that we want people to believe in the free economy in a business, some people make $20 million a year. to your point, the free market system and delivering being a well-run company and delivering great shareholder value is part of that free market system. mr. grothman: i'm sure they are getting good value. do you see what i'm saying? maybe you don't understand what i'm saying. there are a lot of people out

there, we are going to elections, a lot of people out there think that the system is broke because they are working butt off,-- their told to take cuts in pay, and they see a chief executive making a huge amount of money, way more proportionately even adjusting than inflation. i understand it, more than a make in other western countries. gatesthink a -- it rates at someg people. in all walks of life, people have the ability of making more involuntary lease a, -- voluntarily say, i am not going to make that much money. i want you to comment on the system we have in america were so many chief executives seem to be making far more money than i think anybody would even know what to do with. that is my only question.

and i, other than commenting, the free market hope, thereis, i are companies that are giving , giving back and creating access and providing, providing many things, and like i said, i , and what welan have been able to create, and, with 80 billion doses capacity, and lowering health care costs. ms. bresch: you're not answering the question means you are a little bit embarrassed the inside. your last comment on how reducing the price, i find offensive and inaccurate. let me go first, it is epipen a brand drug or a generic drug?

ms. bresch: it is a brand drug. >> does that mean it is an innovator drug? mean based onu cms classification? it is a non-innovator drug. >> those are often really ?enerics, correct # think it is a branded product, but a non-innovator drug for the purpose of cms? ms. bresch: that is how it is classified. mr. chaffetz: your familiar mylan had to settle $118 million settlement that in 2009, right? ms. bresch: i am not familiar. i am trying, what, settlement? mr. chaffetz: with the department of justice to resolve allegations that mylan had underpaid their rebate

obligations in the medicaid prescription drug rebate program with respect to several other mylan products, not epipen, but are you familiar with that? ms. bresch: i am not recalling the settlement that you are speaking of. mr. chaffetz: this is the justice department. i asked consent to enter this into the record. companies,ceutical submissions of false claims to medicaid without objections ordered. um, have you or anybody are mylan spoken with cms? yes, there has been conversations with cms. mr. chaffetz: have you had any of those conversations with cms about epipen or the generic epipen? ms. bresch: i have not. mr. chaffetz: have you spoken

with anybody at health and human services about epipen? ms. bresch: i have not. mr. chaffetz: nobody. have you been in discussions with cms about epipen? ms. bresch: yes, people at the company has talked to staff back and forth. mr. chaffetz: who at your company has done that? ms. bresch: i think there has been several people, i mean, several people within the company that have had conversations. mr. chaffetz: can you get us the names of those people? i am sure we could tell you, yes. mr. chaffetz:: i am sure that we can do that. mr. chaffetz: we would also like the names of the people at cms they have been in discussions with. can you give us the names of the cms people your staff has been working with? ms. bresch: i'm sure we can. mr. chaffetz: is 10 days

reasonable? ms. bresch: sure. mr. chaffetz: the concern here is that, and the question really, is why is mylan classifying epipen as a non-innovator drug? ms. bresch:there have been seves throughout time that confirmed that that is. mr. chaffetz: do you believe the generic that you're planning to introduce, and when by the way, do you hope to introduce the generic? ms. bresch: certainly before the end of the year. mr. chaffetz: in the neck 90 days or something. ms. bresch: yes. to chaffetz: a you going work to classify that as a non-innovator drug or an innovator drug? ms. bresch: i'm much or without classification is. we have not submitted that document. we have not submitted yet because we have not launched the product. mr. chaffetz: i need to spend a few minutes going through this.

this chart that is right next to you. i also need help with you, and it is going to take a few minutes to appreciate the indulgence of the committee to understand some of the definitions. out, there isnted a revenue line which seems to be missing. correct? let me go first to the mylan it revenue. met for me. is that the average revenue? --defined that for me. is that the average revenue? ms. bresch: yes. mr. chaffetz: i will read here. "approximately 85% of consumers who are prescribed and epipen autoinjector payless than $200 for a two unit pack, and a majority play less than -- lessss and $50 -- pay

than $50." is that correct? they are both in the majority, right? 85% were prescribed and epipen payless than $100 for a two unit pack, and the majority payless pay less than $50. ms. bresch: yes. mr. chaffetz: how many do it as a prescription? do you have to have a prescription? ms. bresch: yes. 100% of the: so universe. if your average revenue to mylan , and the majority of people are paying less than $50, the minority is paying what to get it?

it could range from, it could be anything because all of the plans, if you are uninsured or if, it would range because every plan is different. mr. chaffetz: what is the highest number? is the $608 low? ms. bresch: because we do not set the price when you patient walks up to the pharmacy -- mr. chaffetz: i'm talking about your revenue. our revenue is the $224 per pen on average. mr. chaffetz: that is the average. what is the remainder? what are they paying? ms. bresch: the cost to the patient is different than what we are receiving. mr. chaffetz: you just told me, look, you told me that you sell 4 million to pat summitt 8 million individual.

, 8 millions individual. you miraculously get to roughly $1.1 billion. ms. bresch: correct. mr. chaffetz: how is it that the majority, according to what you wrote us, payless and $50, if the majority of 4 million people , more than 2 million people are paying less than $50, how do you get to that? ms. bresch: what the patient is paying is not coming back to mylan. from when we were speaking earlier of the people, the middlemen in the system, that is either the pharmacy benefit managers, retailers, --lesalers, read to insurers, i am not interfacing directly with a price perspective or a paid perspective to the patient.

you'reffetz: representing to us that 85% of consumers are paying less than $100. thanority are paying less $50. the reason you're having this hearing is not because the public thinks they are getting a good deal. look, i got a $600 product and i only had to pay $48. that is not why you are here. they are telling us, they are having to pay much greater numbers. ms. bresch: it is a growing minority i spoke of earlier that is being faced with the wholesale acquisition cost or more at the counter. mr. chaffetz: how do you define profit? what is profit to you? ms. bresch: the $50 per pin profits is then direct epipen cost. there is no allocation off of that. mr. chaffetz: that is not what you wrote me. less thanthis letter a week ago. here's what you said. "among other things, this profit is used to fund research and

development and to maintain and improve our facilities across mylan, in which we invest $1.2 billion this year alone, or more than $3 million every day." that is not the definition of profit. ms. bresch: that is how we reinvest the profit that we make. i fight you are asking me how $50 -- when there are five executives over five years at a $300 million, where in your p&l is that show up? where does it show up? ms. bresch: the $50 number i am showing you per pen is taking no company allocation to that whatsoever. mr. chaffetz: that is what you just wrote to me. you said "this profit is used for --" responsibly that your $50 profit is funding r&d and facilities? i just read to you verbatim what you wrote to me. ms. bresch: we absolutely take

our profits and reinvest in our business. this year alone, $750 million in r&d we are spending. mr. chaffetz: when you take a three hundred million dollars that the five executives got, where on your p&l does that show up? ms. bresch: i am saying that we did not take any of that out of this $50. mr. chaffetz: i'm not talking about the $50. i'm talking about the whole thing. your operating expenses over everything, correct? ms. bresch: correct. mr. chaffetz: where does that show up in that spreadsheet, tell me where that number is. here.esch: it is not on $50 would be lower if we were taking this company allocation like running the business out of this. this is straight just epipen. mr. chaffetz: i'm going to come back to this because your numbers are so askew. it really is troublesome. let me recognize the ranking member, mr. cummings. >> thank you very much.

to be frank with you, you might ,s well take the fifth, too with the kind of information you got here today because i do not think that we, i will tell you, this reminds me of a game when, it is like hiding a ball. and it is like a shell game. it seems like we can never figure out where the ball is, and as i said from the very beginning, i was concerned that is worse.e here rep. cummings: in a row but up

on andon, the boxer hold try to get through. .t the end, he comes back in this situation, not only are you holding on, trying to win, you are placing we are position where not making very much progress here at all. i am saying i have been here 99% of this hearing, and i have practiced law for many years, and i will tell you, i do not know what your lawyers are telling you, but you, i do not think that you have been frank with us. i could understand it a little bit better if you did not know what this hearing was all about, and i do not say those words lightly. let me ask you a few questions, see if we might be able to move

forward here a little bit. you know, your numbers just do not add up. if i could sum up this hearing, it would be the numbers do not add up. it is extremely difficult to believe that you are making only $50 in profit when you just increased the price by more than $100 per pen. do you have any internal company documents to track the total profit you have made off of from 2007, when you acquired it, until today? do you have any of those documents? ms. bresch: well, we certainly could, i sitting here today do not have a cumulative number. i totally understand, and i know

, if i had only read everything that has been out there around the price, i can totally understand how perfect thing it how- help her pick like -- perplexing it is. while i do not have answers to fix all of it, i think i could not agree more with the transparency of the $608 down is needed across the board because, patients have no visibility, pharmacists, nobody has a visibility of the value or what is being paid for what. rep. cummings: hold on for that one little thing you just said. value of thet the medication, right? , i know, you can take that mean, when you talk about the value of a medication, i guess you are saying, if you have a certain medication, it will keep you out of the hospital. certain medications will save your life. where does that end?

in other were, had you put value in other words, how do you put value on life? are saying, you because i am able to save somebody from possibly going to the hospital, whatever, that is supposed to be incorporated in the value and that is partly why we are able to charge these prices. are you telling us you are doing us a favor, you are doing our constituents a favor by raising these prices? i think, hopefully what you will see with the generic coming to the market -- rep. cummings: i'm happy about my now, right now. the other night, i was at a pta meeting in my district, and i had a mother who has three children, and all of them use epipen. she has to have one set at home, one at school. tears,od there in

because she is only making maybe $50,000 a year or less, and she is trying to figure out how she is going to afford this. other listened you more and more and you talk about, i think, i so, i might be a little bit more trustful if i had not heard some of this before, if i had not read some of it before from people who , but now,imbeciles when you present to me that you have got these assistance programs, as i see the assistance programs, and by the way, everybody comes in with the same story. it must be some playbook that you all use, and they say, oh, we have got an assistance program, we are going to help some people, and the next thing you know, they then you use that then use that to

justify not reading the prices down. you understand that? that is exactly what you're coming here to do, you have done, that is what you are doing. are you going to go down on the price or are you going to come back down on the price at all? stuff,de the generic what about coming down on the price? ms. bresch: we believe that the generic was much more meaningful to make sure we are reaching those patients so that across all the access points, and one thing i would say, and i know you have other companies in here, and i know there has been conversations, i would say, just as an example, mylan has had an orphan drug product for years, years and years, and it treats a very small number of patients. i believe it is now $500. it is a rare disorder. aroundice has stayed

annually to00 provide the medicine needed every day, where it company came on the market three years ago at treat that same patient population with just a more convenient dose. arederstand that there three things that you have seen and companies that you have spoken to, but i would hope that you would be able to look at mylan and the role we have played with generics, the role that i play if i talk about our sister gone it -- our sister gone -- if i talk about our experience. in schools and other public places, so that there is an epipen there were epinephrine autoinjector there for anyone who needs it. rep. cummings: we appreciate all of that. thatmylan have a slogan seeing is believing?

ms. bresch: yes. rep. cummings: you do? ms. bresch: yes. rep. cummings: seeing is believing, that is what we want to do, we want to see the records. you are refusing to say how much profit your company makes, you are repeating industry talking points with no substance whatsoever, you are try to claim priceour massive increases are actually a good thing for american families. our committee requested documents from mylan, but so far, you have failed to produce everything we have asked for. as you just said, mylan's slogan is seeing is believing, so in summary, ms. bresch, will you agree today, i know the chairman has asked you to do some next 10s within the

days and information within the next 10 days, will you agree today to produce all the the committee has requested that we can confirm what is going on here? ms. bresch: we will certainly produce everything that we can. rep. cummings: what is that mean? i do not know what that means. you, we have asked for specific documents. ms. bresch: i know we have been responsive and i know we are still, i understand that we have produced thousands of documents, a couple thousand documents, and i know there is more that we have to produce. i am saying that i am sure we will produce everything that we possibly can to give you the visibility and transparency to the numbers that i am showing you here today. rep. cummings: we want your agreements and contracts with manufacturers. we want suppliers. we want distributors, ebm's, and

any of your other partners in the distribution channel for epipen. will you produce those? ms. bresch: i cannot be to all of those contracts from the ity agreement, competitive information in some of those. that is why i have got to rely on the lawyers who are producing the documents to make sure that we are staying compliant with some of the other provisions in the contract. s,p. cummings: you will get u i know you are lawyered up back there, make sure you consult with your lawyers to get is what you can? ms. bresch: yes. rep. cummings: thank you. >> i recognize the gentleman from georgia. >> thank you. i find the chart very interesting. can you hold it up a little more, i cannot see the bottom of it. rebates and allowances, this is what you give back to patients,

and so that is minus $334? ms. bresch: no. are all the same, the pbm, retail, that is all the rebates and things. >> you are giving a rebate to a pbm? ms. bresch: yes. >> that is where that comes in there? >> it is part of it. >> what are allowances? ms. bresch: so, all of the>> fe, there is wholesale or fees, discount, rebate, that is capturing everything between the $608 -- >> are you getting any rebates from pbm? i did not want to give you an inaccurate number.

are you getting rebates from a pbm? yes or no? ms. bresch: we are paying rebates for the pbm. rep. carter: are you getting rebate for a pbm? ms. bresch: we are not getting epipen specific rebates for being the manufacturer. rep. carter: you are not getting rebates from a pbm? ms. bresch: i don't believe so. rep. carter: you just told me earlier you are going to produce documents that would give us the numbers. ms. bresch: what i do not want to confuse is that we are an employer. we have a pdm that is managing all of the employees in the u.s.. what i did not want to give you was an inaccurate number if there was rebates that come from the pbm as an employer versus the manufacturing.

we are paying the rebates for the products. this is amazing. this is amazing. i have never in my life seen such a shell game. am speechless, and that does not happen often. ms. bresch: that is what we have said and encourage to your point thattransparency and where is going and how it works, so that you do know what the cost is. rep. carter: let me ask you one more question, and i will stop. can you hold it up again? you took an oath earlier today saying you would tell the truth. ms. bresch: yes. rep. carter: is that the truth? $50 per pen? ms. bresch: yes. our profit is approximately $50 per pen. chairman,r: mr.

i yield. again, i wouldt like to see a definition of .ebates and allowances i would like to see a definition for each of those numbers. cost of goods sold. what do you include and not include in the number? ms. bresch: that is everything we are paying for partner for the cost of its old. >> -- of it sold. >> that is it? ms. bresch: we are, we have a partner on the product. we pay a price -- >> you buy it as a finished product? ms. bresch: yes. to packay them $69 per ?- two pack of epipens

that is your turnkey price? ms. bresch: yes. rep. chaffetz: what you'd call the cost of $105? marketing, sales, the disease awareness, everything that would be directed to epipen or around anaphylaxis awareness. all of the access programs, that would be all inclusive of everything directly related to epipen. and the number for research and development, you're fixed cost, your variable costs, where does that number show up? on here.h: that is not these are direct epipen related costs. if you look at the entire theany, obviously, that was point i was trying to just say earlier, that this is looking at

a product on a standalone basis versus saying it takes a company or human resources or any other entities to sell the product, that this does not take any of that into consideration. this is just giving you an approximate profit on just from an epipen related perspective. rep. chaffetz: not to pixel much on your own personal compensation, none of this comes out of this number, these numbers, you want us to believe your profit is less than $50? ms. bresch: if you do company allocation and all of that in, yes. not know who: i do the investors of this company are, but i am telling you, this is fishy business, because these things do not add up. we would expect a very professional presentation on these dumbed down versions do not make sense

without the definitions in here. just, it just feels like you are not being candid and honest with congress, who is asking you for some very basic information. allare scrambling uncomfortable, but you know what, we just want some basic information. you does this hole for yourself. dug this hole for yourself. tell me this is all out of your profit line. any responsible p&l would lay this out for us. you can make this thing go away by being honest and candid and we just do not think you are. that is why we are in i don't know what number our and we are asking you to provide more information. do not come here and tell us that you are doing the world a favor by increasing the price from $125 to over $600, and

everybody else is making money but poor old mylan. that just does not smell right. it does not pass the basic sniff test. chairman, i do not think i said we were not making money. we were trying to set the record straight as to the dollar amounts that have been out there around the $608 price to show that we received the $274 and to walk down that. we will happily provide the definitions and that transparency to show you the $50. rep. chaffetz: i just cannot buy the idea that the majority of consumers are paying less than $50. i mean, that is what you are telling us. ms. bresch: right. rep. chaffetz: seeing is believing, the mylan way. show it to us. ms. bresch: that is what our data shows, and we will. rep. chaffetz: we have not seen it.

we appreciate you providing that to us. i have fda questions here. how many abbreviated new drug applications are pending before the fda right now? >> 2300 actions are currently. is theaffetz: how long average wait time for an approval of a generic drug? >> i would like to get the information and get it back u.s. as i can. rep. chaffetz: can you define what, in fairness, what is a reasonable time before we start raising the red flags here? 10 days? >> 10 days sound like a, number, if that is good enough for you. rep. chaffetz: we would appreciate that. mentioned, as you you had some confidentiality agreements. that does not apply to congress, you know that, right? hello? ms. bresch: no, i did not know

that. confidentiality. us.hat does not apply to i am sure your attorneys would work that through. i just want tot, go back and briefly, as i close, with what i said before, i have asked you every kind of way, with the prices come down, and you have basically made it , basically it falls in the , and the valiant people. the company the hearing and go through the motions, at least you tried to answer some questions, but in the end, our constituents still suffer. i hope that when you fly back on your jet, you will think about the mother i told you about or

the people that mr. carter talked about a few minutes ago, trying to just take care of their families. , i try to really look at things from a very, in a way, a very balanced way. rep. cummings: but i can tell you that i have been on this committee for 20 years, and very rarely have i seen a situation it seems that we could not get the answers that we were looking forward to this degree. and what that does is it goes against credibility. and that is a very difficult hurdle. that is why we really do need to see the documents, and what we're trying to do, you can make all the money you want, i just do not like the idea of it being done in a way that is not transparent, and i do not like it being done on the backs of

who can least afford it. you keep trying to convince us that mylan is doing a great favor, but mylan is making money. but to come in and to say that some of the things that you have said, it just makes me, you know, feel that maybe you do not think we are that bright. and that is a sad commentary. so thank you very much, and we look forward to receiving your answers. and documents. >> we will be following up both of you within 10 days. committee stands adjourned. thank you. >> thanks, buddy. >>

announcer: tonight at 9:00, afterwards -- >> the budget problem is such a mess. five or six people will decide the budget for the next month. announcer: talking about his career and academics as well as his political philosophy in his book "american underdog." he is interviewed by the former chair of the republican national committee. >> if the people vote, the key

is here supposed to be a democratic republic. that does not mean you have to win every race, but that there is a fair process. if the votes are far more flowers in your fiscal hawk, you lose. >> once more, we will have a government of, by and for the people. >> we are stronger together. no matter what, remember this, love trumps page. campaign: c-span's 2016 continues on the road to the white house with the first presidential debate, monday night live in new york. beginning at 7:30 p.m. eastern, the preview of the debate, and that at 8:30 a predebate for the audience. not :00 p.m. live coverage of the debate followed by viewer

reaction. the 2016 presidential debate on c-span. watch anytime on-demand at c-span.org, or listen live on the free c-span radio app. announcer: with current federal spending set to expire at the end of the month, the senate will try to move forward on a temporary bill to fund the government through december. here is what senator majority leader mitch mcconnell had to say, which prompted a response from senator mikulski who is ranking member of the center appropriations committee. sen. mcconnell: it is a result of many hours of bipartisan work on both sides of the aisle. it is a fair proposal that funds all correct government ,perations through december 9 while also providing funding for the new legislation we just

passed overwhelmingly, and that the president has signed, legislation to address the hair when an opioid epidemic --heroin and opioid epidemic. this includes states maryland, west virginia, louisiana, and of course it also includes important resources to support our veterans and connecticut. these are resources needed to help promote mosquito control. members will have the next four days to review before any votes are taken in relation to the issue. further, we expect the president to sign or send up a veto message by tomorrow. beginning the process will ensure there is adequate time to finish before the override vote, and before the current government funding runs out next week. then we can turn to the veto

override. to continuing bipartisan cooperation so we can complete our important work on seeker, veterans funding in the clean cr that will fund the government through december 9. >> to senator from maryland. sen. mikulski: i said as the ranking member of the appropriations committee. i just want to say to my colleague, from both sides of the aisle, over the past few weeks, we democrats have negotiated with the republicans to come up with a responsible, contentedly funding resolution that keeps government open through december 9. giving congress time to complete an appropriations process. goal was to respond to compelling, urgent needs, zika, floods in louisiana and also our

national security as well as those things that are important to the economy of the united states of america. sure it did make not include any prohibitions but did contain the continuing funding for veterans and military construction. our negotiations have been cordial and productive. i want to complement the other side of the aisle with their professionalism and their civility. we are now down to a handful of issues, but they are down to the real issues. now, the republican leader, the majority leader has filed a republican only bill to substitute that has now been placed before the senate today. we democrats cannot vote for that senate, for that others to, and urge

vote against it. we want to make sure that we avoid a government shutdown and a government showdown a continue the constructive talks that we have had, but these substitute, offered by the republican majority leader, falls short. what is wrong with the bill before us? the, one, it fails to help people of flint, michigan. 100,000 people in flint, michigan are still waiting for the water to be clean and safe. 9000 children have already had lead exposure that can cause permanent and irreversible damage. know that the people in louisiana has been hit by terrible floods. we do not want to give lip service in response to their needs.

onlyouisiana is not the needs in america. we believe that the people of michigan, the people of flint that have been waiting for more than one year should be included in this continuing resolution. i want to be clear, we do want to help the people of louisiana, but we do want to help the people of flint. the other side of the aisle says flint can be handled two months from now with the water resource development. the houses made no commitment to help flint in that bill. they have not even brought word to the floor action. the people of flint need help now. they actually needed help nine months ago. we fail to pass a infrastructure bill.

baltimoree fund, could do something about their aging water infrastructure and at the same time bring american jobs in our own urban communities. lint'snate passed f funding 95-3 last week. why wait? let's do it. also, democrats continue to fight for flint, and we will not --nd by plus in part of standby partisan riders. i know the 300,000 mariners that tok for the government want stay on the job. i want them to know that we are working hard to keep the government open and avoid a shutdown or a standout.

we need to make sure we help our veterans. we need to make sure we have the funds to fight zika and the terrible challenge of children being born with the most short a and lifelong lifelong, permanent handicaps. we want to help flint. most of all, we know that in a tree in dollars budget -- trillion dollar budget, we have a framework to move ahead. really, serious work has been done here on national security, the funding of the department of defense, the funding of other agencies that contribute to our national security, whether it is the state department in the diplomatic efforts, homeland security, and boy, did they not do a good job responding last weekend to the challenges in new york? but in every community we face

these, and at the same time, agencieslook at the like the national institute of we want them to keep the lights on so they can keep the light of hope going to make sure we find cures for diseases. we will say more about this. we appreciate the republican, the majority leader for continuing conversation with us. we are a work in progress. let's get back to work. let's continue to make progress. we have taken steps forward. let's not take steps sideways or take steps backwards. let's continue making progress. let's get rid of the poison pill riders and come to an agreement on how we can help louisiana and

helpful and with some of these other issues. mr. president, we look forward to more conversation, more , andructive conversation our side of the aisle stands ready to engage in conversations in negotiations, and i urge my colleagues to standby, wish us well so that we can keep doing the job we were elected to do. mr. president, i have concluded my remarks. do we need to go into a quorum? i ask the chair, i note the absence of a quorum. announcer: the senate back tomorrow 3:00 eastern debating the short-term spending bill, a procedural schedule tuesday, 60 votes required to advance. the house is back to :00 eastern discussing several bills that have to do with cyber security,

emergency care for veterans and food security. numbers could take up the senate's version of a temporary spending bill and it is possible they may vote to override the president's veto of the 9/11 victims lawsuit bill. as always, you can wash the house live on c-span and the senate, live on c-span-2. our c-span campaign 2016 is in ohio this week, asking students and voters, what questions would you ask the candidate at the debate? >> i am a state representative in dayton, ohio. the most important issue in the election are all of the higher education and other issues that affect millennials. as the youngest election of -- elected official in ohio, officials in d.c. need to make sure we are creating higher education that is affordable for students and also make sure we do not leave my generation with

$17 trillion in debt in social security medicare will not be there for us when we need it. >> my name is jeremy and i'm a sophomore at otterbein university, and my important issue is education, both at the level.vel in the public i think k-12 education needs to be more accessible, and that all students, regardless of their zip code, race, socioeconomic status, and when to find a way to make college more available. senior and medical laboratory science major. is most important issue health care and where the direction is. and i think one of the most important issues in this year's candidacy is the fact of education. i think fostering it from a young age is something that is important and there are some discrepancies between the candidates we need to hear that

they have to offer. announcer: voices from the road, from c-span. "communicators." chief lobbyist for at&t talks about the issues he has worked on, the future of telecommunications and why he feels the fcc has become more politicized. he is interviewed by howard buskirk, executive senior editor at two medications daily. >> you have groups at each extreme that seek to prevent it and view compromise as portrayal. frankly, compromise is the art of government it is necessary to solve problems. i think frankly that has leached over into code communications and it is one of the reasons we are seeing this level of polarization and politicization. announcer: watch the communicators, monday night on

c-span-2. here on c-span, newsmakers this next with republican congressman jim jordan of ohio. after that, after sally then donald trump attends a rally in roanoke, virginia. at 8:00, our conversation with robert samuels than on q&a. on q&a.robert samuelson is congressman jim jordan. -- >> our guest this week is congressman jim jordan. the ohio republican chairs the house freedom caucus. his committees include government oversight and reform and the judiciary committee. let me introduce the two reporters that will be joining us this week. rachel covers congress for politico. kelsey is a washington post congressional reporter. before we delve into questions we want to talk about charlotte. once again this week we are tuned in watching an american